Small molecules that block bacterial toxin formation have shown promise against Gram-positive bacteria in mouse models.
Browsing: Basic > Drug Development
Researchers from Purdue University have reported that antimicrobial photodynamic therapy using a fluorescent analog of heme, could be an alternative for treating MRSA infections.
In this interview, we speak to to Keith Kaye, Principle Investigator of the RESTORE-1 trial assessing relebactam in combination with imipenem (IMI/REL), about the trial’s results and the implications these have for clinicians in ‘real world’ settings.
The US FDA has approved Paratek Pharmaceuticals’ antibiotic Nuzyra™ (omadacycline) for the treatments of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
A Phase III study, TANGO II, has reported that meropenem–vaborbactam monotherapy for CRE infections was associated with improvement in clinical cure rates, lower nephrotoxicity and lower mortality versus best-available therapy.
GARDP and Novartis have announced a partnership hoping to accelerate the development and availability of generic antibiotics for children in LMICs.
Researchers from Genentech have carried out optimization of the arylomycins, uncovering a molecule with potent, broad-spectrum activity against Gram-negative bacteria.
A team of researchers from Imperial College London (UK) have identified compounds which prevent the malarial parasite sexually maturing inside the mosquito.
Merck’s antibiotic ZERBAXA® (ceftolozane and tazobactam) has met its primary endpoint of non-inferiority compared with meropenem in a Phase III trial of patients with hospital-acquired and ventilator-associated bacterial pneumonia.
Scientists at the University of Manchester (UK) have developed the first non-antibiotic drug to successfully treat tuberculosis (TB) in animal…